June 2017 VOL 8, NO 6

Letters from Lillie

We Are Stronger Together! Get Involved in Your AONN+ Community

Lillie D. Shockney, RN, BS, MAS, ONN-CG 

Dear Navigators, I’ve just returned from our West Coast Regional Meeting, where attendees enjoyed a robust agenda featuring speakers from across the oncology community. I cannot help but feel re-energized [ Read More ]

Original Research

Perceived Economic Hardship and Distress in Acute Myelogenous Leukemia

Justin E. Bala-Hampton, DNP, MPH, RN, AGACNP-BC1; Linda Dudjak, PhD, RN1; Tara Albrecht, PhD, ACNP-BC, RN2; Margaret Q. Rosenzweig, PhD, FNP-BC, AOCNP, FAAN1
1School of Nursing, University of Pittsburgh, Pittsburgh, PA
2Virginia Commonwealth University School of Nursing, Richmond, VA 

Background: Multiple studies have quantified the direct and indirect costs and related patient hardship and distress in general cancer care; however, little attention has been focused on a particular cancer [ Read More ]

Evidence into Practice

Professional Roles and Responsibilities

Cheryl Bellomo, MSN, RN, OCN, ONN-CG 

The identification of barriers to care was a primary focus of patient navigation instituted in the 1990s by Harold P. Freeman, MD, to help explain delays in diagnosis as well [ Read More ]

Evidence into Practice

Novice Navigator: Case Scenario on Professional Roles and Responsibilities

Eugenia Artice, RN-BC, BSN; Pam Goetz, BA, OPN-GC; Marian E. Gilmore, RN, OCN, ONN-CG; Barbara McHale, RN, BS, OCN, ONN-CG, CBCN 

The leadership in oncology administration and the patient experience department at a community hospital identified coordination of care as an area for improvement for patients with brain cancer. The standard [ Read More ]

Evidence into Practice

Seasoned Navigator: Case Scenario on Professional Roles and Responsibilities

Tricia Strusowski, RN, MS 

Susan is a new navigator at her cancer center; she is assigned to patients with head and neck cancer. Her preceptor is Mary, a navigator with 10 years’ experience. Susan [ Read More ]

2017 Genitourinary Cancers Symposium

Adding Cisplatin to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer

The addition of cisplatin to standard therapy with gemcitabine and nab-paclitaxel was associated with a median overall survival that “has not been seen in stage IV pancreatic cancer,” according to [ Read More ]

2017 ACCC Annual Meeting: CANCERSCAPE, AONN+ Standardized Metrics

What’s New in Navigation: New Metrics and Physician Collaboration

Historically, there has been a gap in the literature to measure the success and impact of patient navigation programs, but the Standardized Metrics Task Force of the Academy of Oncology [ Read More ]